Lyomark Pharma GmbH

Alveofact is used in neonates. Preventive use in premature neonates with a high risk of respiratory distress syndrome (RDS).
Active substance: Phospholipid fractionfrom bovine lung (surfactant)

Neofact is an innovative applicator for instillation of surfactant and is used for the management of respiratory distress syndrome (RDS) in preterm and term neonates:

• Simple and practical handling • Application of surfactant without Magill forceps • Precise positioning in ...

Neofact, by Lyomark Pharma, is a medical device for neonates suffering from RDS. 
This study shows that the LISA method (less invasive surfactant administration) via Neofact® appears feasible. 

Neofact® makes surfactant application easy and is also suitable for all gesta...

Neofact, by Lyomark Pharma, is a medical device for neonates suffering from RDS. 
This study shows that the LISA method (less invasive administration) via Neofact® appears feasible. 

Neofact® makes surfactant application easy and can also be used at any gestational age.

https://pubmed.ncbi.nlm.nih.gov/33023914/

In the clinical study carried out at the University Hospital Tübingen, 20 premature infants (gestational age ≥26 + 0/7) were administered surfactant Alveofact® (45 mg / mL; Lyomark Pharma, Oberhaching, Germany) using the new LISA application aid Neofact®. The aim of developing Neofact® was to enable a simple and gentle process for surfactant application that works without the use of Magill forceps. Neofact® makes surfactant application easy and is also suitable for all gestational ages. This was confirmed in the study and the results of the study are convincing. An extremely high success rate could be achieved (95%), complications seemed rear.

Further information on the study can be found: https://pubmed.ncbi.nlm.nih.gov/33023914/